Table II.
Clinical characteristics by quartiles of mean AMACR intensity of men diagnosed with prostate cancer in PHS and HPFS, 1983–2009
| Quartiles of AMACR intensity (TMA-adjusted z-score)
|
|||||
|---|---|---|---|---|---|
| Highest expression (Q1) | Q2 | Q3 | Lowest expression (Q4) | ||
| Intensity z-score (min-max) | (0.61, 2.94) n=230 |
(+0.06, 0.61) n=230 |
(−0.57, +0.05) n=230 |
(−4.46, −0.58) n=230 |
|
| Characteristics | p-value | ||||
| AMACR intensity | 150.5 (0.90) | 134.5 (0.48) | 124.3 (0.43) | 104 (0.84) | -- |
| AMACR intensity z-score | 1.20 (0.03) | 0.32 (0.01) | −0.23 (0.01) | −1.29 (0.04) | -- |
| Age at diagnosis (yrs) | 65.0 (0.4) | 65.7 (0.4) | 66.1 (0.4) | 66.8 (0.4) | 0.02 ** |
| Body mass index (baseline) | 24.9 (0.2) | 25.1 (0.2) | 24.9 (0.2) | 25.2 (0.2) | 0.79 ** |
| Follow-up time (yrs) | 11.2 (0.3) | 11.4 (0.3) | 11.5 (0.3) | 11.2 (0.3) | 0.82 ** |
| log(PSA at diagnosis) (ng/mL) | 2.0 (0.1) | 1.8 (0.1) | 2.0 (0.1) | 2.2 (0.1) | 0.003 ** |
| missing (%) § | 33 (14.4) | 31 (13.5) | 36 (15.7) | 50 (21.7) | |
| Gleason score | |||||
| 4–6 | 79 (34.4) | 87 (37.8) | 77 (33.5) | 79 (34.4) | 0.11 † |
| 7 | 124 (53.9) | 110 (47.8) | 114 (49.6) | 103 (44.8) | |
| 8–10 | 24 (10.4) | 28 (12.2) | 35 (15.2) | 43 (18.7) | |
| missing (%) | 3 (1.3) | 5 (2.2) | 4 (1.7) | 5 (2.2) | |
| Clinical stage | |||||
| T1, NX/NO | 109 (47.4) | 118 (51.3) | 112 (48.7) | 104 (45.2) | 0.06† |
| T2, NX/NO | 99 (43.0) | 90 (39.1) | 95 (41.3) | 84 (36.5) | |
| T3/T4 or N1/M1 | 10 (4.4) | 12 (5.2) | 10 (4.4) | 30 (13.0) | |
| missing (%) | 12 (5.2) | 10 (4.4) | 13 (5.7) | 12 (5.2) | |
| Prostate cancer death | |||||
| Yes | 16 (7.0) | 11 (4.8) | 16 (7.0) | 25 (10.9) | 0.07 ‡ |
| No | 214 (93.0) | 219 (95.2) | 214 (93.0) | 205 (89.1) | |
**
F-test for analysis of variance, test for trend
†
Global chi-squared test
‡
chi-square test for trend across quartiles